Description
Added on the 24/11/2020 13:00:00 - Copyright : EFE Inglés
A manufacturing error is raising concerns about a promising COVID-19 vaccine being developed. The vaccine was developed by pharmaceutical company AstraZeneca and the University of Oxford. Less than a week after we learned about it, the developers have admitted to a manufacturing error. The error resulted from two different doses during the recently concluded phase III trial. AstraZeneca and the University of Oxford described the vaccine as being 70% effective. However, that number now seems a bit misleading but not necessarily in a bad way.
Tokyo, May 19 (EFE/EPA).- The Tokyo stock benchmark Nikkei briefly rose over 500 points during the trading on Tuesday due to expectation for vaccine development of the COVID-19 coronavirus, before ending at 20,433.45 points, up 299.72 points or 1.49 percent(Camera: KIMIMASA MAYAMA).FOOTAGE SHOWS PEDESTRIANS WALKING PAST A SCREEN SHOWING CLOSING INFORMATION OF TOKYO'S NIKKEI STOCK AVERAGE, WHILE THE JAPANESE CAPITAL IS STILL UNDER CORONAVIRUS STATE OF EMERGENCY, IN TOKYO, JAPAN.
|
Support : Technical 
- Content 
- Editors 
